CO2019000686A2 - Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo - Google Patents
Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridiniloInfo
- Publication number
- CO2019000686A2 CO2019000686A2 CONC2019/0000686A CO2019000686A CO2019000686A2 CO 2019000686 A2 CO2019000686 A2 CO 2019000686A2 CO 2019000686 A CO2019000686 A CO 2019000686A CO 2019000686 A2 CO2019000686 A2 CO 2019000686A2
- Authority
- CO
- Colombia
- Prior art keywords
- triazolo
- pyridinyl
- compounds substituted
- indole compounds
- tals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula (I) (I) o una sal del mismo, en donde R1, R2, R3, R4, R5, m, n y p se definen en la presente. También se describen métodos para usar tals compuestos como inhibidores de la señalización a través del receptor tipo Toll 7, 8 o 9, y composiciones farmacéuticas que comprenden tals compuestos. Estos compuestos son útiles para tratar enfermedades inflamatorias y autoinmunitarias.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611022328 | 2016-06-29 | ||
| US15/635,055 US10071079B2 (en) | 2016-06-29 | 2017-06-27 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| PCT/US2017/039633 WO2018005586A1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019000686A2 true CO2019000686A2 (es) | 2019-02-19 |
Family
ID=60805851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0000686A CO2019000686A2 (es) | 2016-06-29 | 2019-01-24 | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US10071079B2 (es) |
| EP (1) | EP3478682B1 (es) |
| JP (1) | JP6995067B6 (es) |
| KR (1) | KR102473482B1 (es) |
| CN (1) | CN109641895B (es) |
| AR (1) | AR108905A1 (es) |
| AU (1) | AU2017287902B2 (es) |
| BR (1) | BR112018077119A2 (es) |
| CA (1) | CA3029620A1 (es) |
| CL (1) | CL2018003821A1 (es) |
| CO (1) | CO2019000686A2 (es) |
| CY (1) | CY1124514T1 (es) |
| DK (1) | DK3478682T3 (es) |
| EA (1) | EA037530B1 (es) |
| ES (1) | ES2886964T3 (es) |
| HR (1) | HRP20211261T8 (es) |
| HU (1) | HUE056091T2 (es) |
| IL (1) | IL263961B (es) |
| LT (1) | LT3478682T (es) |
| MX (1) | MX2018015422A (es) |
| MY (1) | MY196474A (es) |
| PE (1) | PE20190324A1 (es) |
| PL (1) | PL3478682T3 (es) |
| PT (1) | PT3478682T (es) |
| RS (1) | RS62292B1 (es) |
| SG (1) | SG11201811590RA (es) |
| SI (1) | SI3478682T1 (es) |
| TW (1) | TWI636053B (es) |
| UY (1) | UY37310A (es) |
| WO (1) | WO2018005586A1 (es) |
| ZA (1) | ZA201900571B (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| CA3031675A1 (en) | 2016-07-30 | 2018-02-08 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors |
| KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
| CR20190181A (es) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. |
| KR102651947B1 (ko) | 2017-08-04 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물 |
| US11130756B2 (en) | 2017-08-04 | 2021-09-28 | Bristol-Myers Squibb Company | [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds |
| JP7265554B2 (ja) * | 2017-11-14 | 2023-04-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
| ES2927960T3 (es) * | 2017-12-15 | 2022-11-14 | Bristol Myers Squibb Co | Compuestos de indol éter sustituidos |
| WO2019126113A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Substituted indole compounds useful as tlr inhibitors |
| MX2020005515A (es) | 2017-12-19 | 2020-09-03 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr). |
| AU2018390543A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| AU2018390544A1 (en) | 2017-12-20 | 2020-08-06 | Bristol-Myers Squibb Company | Diazaindole compounds |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CA3086431A1 (en) * | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112585134A (zh) * | 2018-06-13 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡啶基杂环基化合物 |
| JP7366994B2 (ja) | 2018-07-23 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
| CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
| KR20210080461A (ko) * | 2018-10-24 | 2021-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 및 인다졸 화합물 |
| ES2963696T3 (es) * | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CN113227089A (zh) | 2018-10-31 | 2021-08-06 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
| CN113574063A (zh) | 2019-03-07 | 2021-10-29 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3966212A1 (en) | 2019-05-07 | 2022-03-16 | Bristol-Myers Squibb Company | Prodrug compounds |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN110146631B (zh) * | 2019-06-25 | 2021-11-12 | 山西康宝生物制品股份有限公司 | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| WO2021067657A1 (en) * | 2019-10-04 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
| WO2021252718A1 (en) | 2020-06-11 | 2021-12-16 | Bristol-Myers Squibb Company | Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus |
| IL299147A (en) | 2020-06-22 | 2023-02-01 | Bristol Myers Squibb Co | Treatment of rheumatoid arthritis |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| CA3200155A1 (en) | 2020-11-26 | 2022-06-02 | Xiaomin Zhang | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| EP4323369A1 (en) | 2021-04-16 | 2024-02-21 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合 |
| CN113416188B (zh) * | 2021-05-31 | 2022-12-13 | 河南偶联生物科技有限公司 | 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2024015825A1 (en) | 2022-07-13 | 2024-01-18 | Bristol-Myers Squibb Company | Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL349192A1 (en) | 1998-12-18 | 2002-07-01 | Axys Pharmaceuticals | Protease inhibitors |
| JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター（ｔｌｒ）アンタゴニスト |
| US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| AU2007234399A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| ATE495743T1 (de) | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| JP5529876B2 (ja) | 2008-10-17 | 2014-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物 |
| SG173639A1 (en) | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| AU2010258785A1 (en) | 2009-06-10 | 2012-01-19 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| WO2011009015A1 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
| PL2663555T3 (pl) | 2011-01-12 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
| AU2012205486B2 (en) | 2011-01-12 | 2017-02-02 | Array Biopharma, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| US9353115B2 (en) | 2011-06-01 | 2016-05-31 | Janus Biotherapeutics, Inc. | Immune system modulators |
| JP6093759B2 (ja) | 2011-06-01 | 2017-03-08 | ジャナス バイオセラピューティクス，インク． | 新規の免疫系調節剤 |
| EA031618B1 (ru) | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
| TR201808033T4 (tr) * | 2011-07-13 | 2018-06-21 | Tiumbio Co Ltd | Alk5 ve veya alk4 inhibitörleri olarak 2 pridil ikameli imidazollar. |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| AU2013261267B2 (en) | 2012-05-18 | 2017-06-29 | Sumitomo Pharma Co., Ltd. | Carboxylic acid compounds |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| US9643967B2 (en) | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| RS64286B1 (sr) | 2016-06-29 | 2023-07-31 | Kezar Life Sciences | Kristalne soli inhibitora imunoproteazoma za peptid epoksiketon |
| CA3029518A1 (en) | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
| CA3031675A1 (en) | 2016-07-30 | 2018-02-08 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors |
| KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
| US11130756B2 (en) | 2017-08-04 | 2021-09-28 | Bristol-Myers Squibb Company | [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds |
| KR102651947B1 (ko) | 2017-08-04 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물 |
| JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
| ES2927960T3 (es) | 2017-12-15 | 2022-11-14 | Bristol Myers Squibb Co | Compuestos de indol éter sustituidos |
| CN111819176B (zh) | 2017-12-18 | 2023-12-15 | 百时美施贵宝公司 | 4-氮杂吲哚化合物 |
| MX2020005515A (es) | 2017-12-19 | 2020-09-03 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr). |
| WO2019126113A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Substituted indole compounds useful as tlr inhibitors |
| AU2018390543A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| AU2018390544A1 (en) | 2017-12-20 | 2020-08-06 | Bristol-Myers Squibb Company | Diazaindole compounds |
| CA3086431A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| KR20210080461A (ko) | 2018-10-24 | 2021-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 및 인다졸 화합물 |
-
2017
- 2017-06-27 US US15/635,055 patent/US10071079B2/en not_active Ceased
- 2017-06-28 SG SG11201811590RA patent/SG11201811590RA/en unknown
- 2017-06-28 SI SI201730890T patent/SI3478682T1/sl unknown
- 2017-06-28 BR BR112018077119-8A patent/BR112018077119A2/pt unknown
- 2017-06-28 PE PE2018003329A patent/PE20190324A1/es unknown
- 2017-06-28 MY MYPI2018002975A patent/MY196474A/en unknown
- 2017-06-28 JP JP2018568837A patent/JP6995067B6/ja active Active
- 2017-06-28 AR ARP170101788A patent/AR108905A1/es unknown
- 2017-06-28 PL PL17737442T patent/PL3478682T3/pl unknown
- 2017-06-28 CA CA3029620A patent/CA3029620A1/en active Pending
- 2017-06-28 AU AU2017287902A patent/AU2017287902B2/en active Active
- 2017-06-28 TW TW106121570A patent/TWI636053B/zh active
- 2017-06-28 DK DK17737442.8T patent/DK3478682T3/da active
- 2017-06-28 EA EA201990048A patent/EA037530B1/ru not_active IP Right Cessation
- 2017-06-28 MX MX2018015422A patent/MX2018015422A/es active IP Right Grant
- 2017-06-28 KR KR1020197002353A patent/KR102473482B1/ko active IP Right Grant
- 2017-06-28 PT PT177374428T patent/PT3478682T/pt unknown
- 2017-06-28 ES ES17737442T patent/ES2886964T3/es active Active
- 2017-06-28 WO PCT/US2017/039633 patent/WO2018005586A1/en unknown
- 2017-06-28 LT LTEPPCT/US2017/039633T patent/LT3478682T/lt unknown
- 2017-06-28 CN CN201780052726.1A patent/CN109641895B/zh active Active
- 2017-06-28 UY UY0001037310A patent/UY37310A/es unknown
- 2017-06-28 RS RS20211090A patent/RS62292B1/sr unknown
- 2017-06-28 HU HUE17737442A patent/HUE056091T2/hu unknown
- 2017-06-28 EP EP17737442.8A patent/EP3478682B1/en active Active
-
2018
- 2018-07-23 US US16/042,116 patent/US10478424B2/en not_active Ceased
- 2018-12-25 IL IL263961A patent/IL263961B/en active IP Right Grant
- 2018-12-27 CL CL2018003821A patent/CL2018003821A1/es unknown
-
2019
- 2019-01-24 CO CONC2019/0000686A patent/CO2019000686A2/es unknown
- 2019-01-28 ZA ZA2019/00571A patent/ZA201900571B/en unknown
- 2019-10-15 US US16/653,297 patent/US10912766B2/en not_active Ceased
-
2020
- 2020-12-07 US US17/113,495 patent/US11672780B2/en active Active
-
2021
- 2021-08-04 HR HRP20211261TT patent/HRP20211261T8/hr unknown
- 2021-09-15 CY CY20211100814T patent/CY1124514T1/el unknown
-
2022
- 2022-01-25 US US17/584,139 patent/USRE49880E1/en active Active
- 2022-01-25 US US17/584,155 patent/USRE49893E1/en active Active
- 2022-01-25 US US17/584,147 patent/USRE49931E1/en active Active
-
2023
- 2023-04-26 US US18/307,119 patent/US20230255941A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019000686A2 (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| EA202091474A1 (ru) | Замещенные индольные соединения, применимые в качестве ингибиторов tlr | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| EA201990169A1 (ru) | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| EA202091479A1 (ru) | Арил- и гетероарилзамещенные индольные соединения | |
| EA202091483A1 (ru) | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr | |
| CL2019001664A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. | |
| CL2018000293A1 (es) | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
| PE20141791A1 (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| SV2011003997A (es) | Pirimidinas fusionadas | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| CL2021000296A1 (es) | Inhibidores tipo indol y azaindol de enzimas pad. |